SciClone Pharmaceuticals Inc. (SCLN) said the company and its partner Sigma-Tau S.p.A. received initial topline results in a clinical study evaluating the potential of ZADAXIN to improve immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria from Novartis.
ZADAXIN is SciClone's synthetic preparation of thymalfasin, a peptide produced by the thymus gland that circulates in the blood naturally and is instrumental in immune responses.
The randomized, 3-arm open label study has a planned duration of 6 months and hence is still ongoing and is being conducted in patients with end-stage renal disease who are on chronic dialysis. SciClone Pharma stated that this ongoing study is designed to evaluate efficacy based on the proportion of patients achieving seroconversion, a significant rise in specific antibody titers against H1N1 influenza.
According to investigators, at 21 days following vaccination, 89% of patients in the low-dose ZADAXIN arm achieved seroconversion as did 88% of patients in the high-dose ZADAXIN arm, compared to only 56% of patients in the vaccine-only arm of the study, the company noted.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.